Skip to main content

The Radoff-JEC Group Urges Seer, Inc. Stockholders to Vote for Boardroom Change Today

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Believes New Independent Directors Are Needed to Correct the Board’s Misaligned Priorities and Prevent Further Value Destruction

Reveals Seer’s Board Has Not Responded to the Radoff-JEC Group’s Stockholder-Friendly Offer Made on June 15 to Resolve the Ongoing Proxy Contest, Demonstrating the Board's Focus on its Own Entrenchment

Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group” or “we”), who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) (“Seer” or the “Company”), today issued the following statement.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624630276/en/

Source: FactSet, Company proxy statements. Graph and figures are from December 4, 2020 through December 31, 2025.

Source: FactSet, Company proxy statements. Graph and figures are from December 4, 2020 through December 31, 2025.

  • Seer’s Board of Directors (the “Board”) has destroyed value for stockholders while enriching Company insiders:
    • The Company has posted a -97.0% share price decline since its December 2020 IPO.1
    • Seer has generated cumulative reported losses exceeding $465 million since its IPO.2
    • Seer has delivered virtually no revenue growth over the last three fiscal years, while investing over $160 million.3
    • The Board has rewarded Chairman and CEO Omid Farokhzad, M.D. with nearly $37 million in cumulative compensation while a stockholder who purchased one share at the time of the IPO ($19.00) would be left with less than $0.63.4
  • Seer has no plan to create stockholder value under Chairman and CEO Omid Farokhzad, M.D.:
    • Dr. Farokhzad has destroyed more than $1 billion in investor capital across five separate companies, evidence supporting our belief that he is incapable of turning around Seer.5
    • The strategic plan overseen by the Board anticipates Seer will not achieve profitability until 2031.6
    • The Board rejected our three proposals to acquire Seer for premiums of 33% - 42% to its unaffected share price and a contingent value right – proposals which we believe provide substantially greater certainty of value creation than the Company’s current strategic plan – without even engaging with us.
  • Seer’s Board has not responded to our proposal to settle this proxy contest:
    • On June 15, 2026, we proposed to end our ongoing proxy contest in exchange for Seer adopting governance enhancements and conducting a tender offer for 20 million shares at $2.50 per share, which would be in line with the Board’s authorized buyback program and management’s statements that there is a “significant dislocation” in the Company’s share price.7
    • More than a week later, the Board has still not responded to our settlement offer – which it requested in the first place – demonstrating that its priority is not delivering value or governance improvements for stockholders.
    • Instead of focusing on opportunities to maximize value for stockholders as Seer’s share price has consistently traded at a significant discount to net cash, the Board has diluted stockholders by repeatedly issuing large grants of restricted stock units and in-the-money options to Dr. Farokhzad and President and CFO David Horn.

Vote FOR the Radoff-JEC Group’s Nominees – Howard H. Berman, Ph.D., Joshua S. Horowitz and Luis E. Rinaldini – Today to Prevent Further Value Destruction

Do NOT Vote for Omid Farokhzad, M.D., Terrance McGuire or Dipchand (Deep) Nishar

Questions about how to vote? Contact (888) 368-0379 or info@saratogaproxy.com.

Visit www.SaratogaProxy.com/SEER to learn more.

_________________________________________

1FactSet. Share price decline from December 4, 2020 through April 10, 2026, the trading day immediately prior to the Radoff-JEC Group’s submission of its initial proposal to acquire the Company.

2 The Company’s Form 10-K for the year ended December 31, 2025 filed on March 2, 2026.

3 Company Form 10-K filings.

4 Company proxy statements. FactSet; share price decline from December 4, 2020 through December 31, 2025.

5 Seer, BIND Therapeutics, Inc., Selecta Biosciences, Inc., Tarveda Therapeutics, Inc. and Senti Biosciences Holdings, Inc.

6 Company PRE 14A filed on October 10, 2025.

7 On the Company’s Q1 2026 earnings call held on May 13, 2026, President and CFO David Horn said: “Our opportunistic share repurchase in the quarter reflect our continued belief that there is a significant dislocation in our share price.”

 

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  241.17
+7.06 (3.02%)
AAPL  298.06
+3.76 (1.28%)
AMD  521.14
+1.29 (0.25%)
BAC  57.43
-0.48 (-0.83%)
GOOG  349.45
+3.37 (0.97%)
META  563.60
+1.40 (0.25%)
MSFT  373.67
-0.27 (-0.07%)
NVDA  200.71
+0.67 (0.33%)
ORCL  157.79
-7.37 (-4.46%)
TSLA  381.14
-0.47 (-0.12%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.